BTIG lowered the firm’s price target on Evolus (EOLS) to $13 from $18 and keeps a Buy rating on the shares. The firm is updating its model to reflect updated 2026 and long-term guidance while noting that rebasing the market size and outlook was an appropriate step following steep declines across the aesthetic injectables category in 2025, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus price target lowered to $17 from $20 at Stifel
- Evolus: Realistic Guidance Reset and Durable Growth Drivers Support Buy Rating and $20 Target
- Midday Fly By: Job growth comes in below forecasts in December
- Evolus narrows FY25 revenue view to $295.5M-$297.5M from $295M-$305M
- Evolus sees FY26 revenue $327M-$337M, consensus $351.66M